Publication | Open Access

Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

Low-dose IpilimumabMedicineImmunologyColorectal CancerPathologyMetastatic Colorectal CancerImmune Checkpoint InhibitorCancer TreatmentDurable Clinical BenefitOncologyRadiation Oncology